Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Tvardi Therapeutics (TVRD) EBITDA (2016 - 2025)

Tvardi Therapeutics' EBITDA history spans 13 years, with the latest figure at -$7.3 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 42.76% to -$7.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$13.5 million, a 75.75% increase, with the full-year FY2025 number at -$18.2 million, up 38.07% from a year prior.
  • EBITDA hit -$7.3 million in Q4 2025 for Tvardi Therapeutics, down from -$5.5 million in the prior quarter.
  • Over the last five years, EBITDA for TVRD hit a ceiling of $4.2 million in Q2 2025 and a floor of -$33.7 million in Q4 2021.
  • Historically, EBITDA has averaged -$18.1 million across 5 years, with a median of -$23.3 million in 2021.
  • Biggest five-year swings in EBITDA: plummeted 2211.92% in 2022 and later soared 159.53% in 2025.
  • Tracing TVRD's EBITDA over 5 years: stood at -$33.7 million in 2021, then rose by 11.49% to -$29.9 million in 2022, then dropped by 7.69% to -$32.2 million in 2023, then surged by 60.49% to -$12.7 million in 2024, then skyrocketed by 42.76% to -$7.3 million in 2025.
  • Business Quant data shows EBITDA for TVRD at -$7.3 million in Q4 2025, -$5.5 million in Q3 2025, and $4.2 million in Q2 2025.